Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug–Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole

[1]  Shiew-Mei Huang,et al.  Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology. , 2019, Journal of pharmaceutical sciences.

[2]  P. Zhao,et al.  Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug–Drug Interactions Involving Enzyme Modulation , 2018, Clinical Pharmacokinetics.

[3]  J. S. Min,et al.  Prediction of drug–drug interaction potential using physiologically based pharmacokinetic modeling , 2017, Archives of Pharmacal Research.

[4]  Xiaomei Zhuang,et al.  PBPK modeling and simulation in drug research and development , 2016, Acta pharmaceutica Sinica. B.

[5]  L. Dean.  Esomeprazole Therapy and CYP2C19 Genotype , 2016 .

[6]  J. Polli,et al.  Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine. , 2015, Journal of pharmaceutical sciences.

[7]  Fang Liu,et al.  In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer. , 2015, International journal of pharmaceutics.

[8]  Sebastian Polak,et al.  Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  Shiew-Mei Huang,et al.  Predicting Nonlinear Pharmacokinetics of Omeprazole Enantiomers and Racemic Drug Using Physiologically Based Pharmacokinetic Modeling and Simulation: Application to Predict Drug/Genetic Interactions , 2014, Pharmaceutical Research.

[10]  H. Blume,et al.  Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update , 2014, Drug Safety.

[11]  N. Isoherranen,et al.  Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions , 2013, Drug Metabolism and Disposition.

[12]  L Zhang,et al.  Predicting Drug Interaction Potential With a Physiologically Based Pharmacokinetic Model: A Case Study of Telithromycin, a Time‐Dependent CYP3A Inhibitor , 2012, Clinical pharmacology and therapeutics.

[13]  A. Rostami-Hodjegan,et al.  The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel , 2011, Drug Metabolism and Disposition.

[14]  Michael A. Rodriguez,et al.  The Effect of Acid Reduction With a Proton Pump Inhibitor on the Pharmacokinetics of Lopinavir or Ritonavir in HIV‐Infected Patients on Lopinavir/Ritonavir‐Based Therapy , 2010, Journal of clinical pharmacology.

[15]  H. Echizen,et al.  Drug-Drug Interaction Profiles of Proton Pump Inhibitors , 2010, Clinical pharmacokinetics.

[16]  Chuang Lu,et al.  The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America , 2009, Drug Metabolism and Disposition.

[17]  T. Andersson,et al.  Stereoselective Disposition of Proton Pump Inhibitors , 2008, Clinical drug investigation.

[18]  M. Hayakari,et al.  Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations , 2007, European Journal of Clinical Pharmacology.

[19]  Marie M. Ahlström,et al.  Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[20]  T. Andersson,et al.  A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects , 2004, European Journal of Clinical Pharmacology.

[21]  M. Danhof,et al.  Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects , 2004, European Journal of Clinical Pharmacology.

[22]  M. Kendall,et al.  The intra- and inter-subject variability of Nifedipine pharmacokinetics in young volunteers , 2004, European Journal of Clinical Pharmacology.

[23]  M. Kasuga,et al.  Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. , 2002, Biological & pharmaceutical bulletin.

[24]  T. Andersson,et al.  Pharmacokinetic Studies with Esomeprazole, the (S)-Isomer of Omeprazole , 2001, Clinical pharmacokinetics.

[25]  A. Suri,et al.  Effect of Omeprazole on the Metabolism of Cilostazol , 1999, Clinical pharmacokinetics.

[26]  D. Flockhart,et al.  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[27]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.

[28]  D. Jones,et al.  Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. , 1985, Gastroenterology.